MedTrace Logo

OSCA - Olaparib Standard of CAre Study

NCT02262273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2123

Last updated 2017-03-01

No results posted yet for this study

Summary

This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. The objectives are to describe in a real-world population, treatment patterns, BRCA mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects

Conditions

  • Platinum-sensitive Recurrent Serous Ovarian Cancer

Interventions

OTHER

Data Collection

Colleciton of data from medical records only

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • A+A Healthcare Marketing Research

    collaborator INDUSTRY

  • Freelance CRA (FCRA)

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Nicoletta Colombo, MD · Steering Committee/Advisory Board Members

  • Laurence Gladieff, MD · Steering Committee/Advisory Board Members

  • Sven Mahner, MD · Steering Committee/Advisory Board Members

  • Isabel Bover, MD · Steering Committee/Advisory Board Members

  • Jacob Korach, MD · Steering Committee/Advisory Board Members

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Australia
  • Belgium
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Portugal
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262273 on ClinicalTrials.gov